Global CD30 (TNFRSF8) Antibody Market Growth 2022-2028
CD30 (TNFRSF8) Antibody is an unconjugated antibody to CD30.
The global market for CD30 (TNFRSF8) Antibody is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC CD30 (TNFRSF8) Antibody market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States CD30 (TNFRSF8) Antibody market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe CD30 (TNFRSF8) Antibody market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China CD30 (TNFRSF8) Antibody market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key CD30 (TNFRSF8) Antibody players cover Sino Biological, Inc., Bio-Techne, Thermo Fisher Scientific (China) Co., Ltd., Boster Biological Technology and MyBiosource, Inc., etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global CD30 (TNFRSF8) Antibody market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global CD30 (TNFRSF8) Antibody market, with both quantitative and qualitative data, to help readers understand how the CD30 (TNFRSF8) Antibody market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the CD30 (TNFRSF8) Antibody market and forecasts the market size by Type (Monoclonal Antibody and Polyclonal Antibody,), by Application (Flow Cytometry, ELISA, Western Blot and Immunofluorescence), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Monoclonal Antibody
Polyclonal Antibody
Segmentation by application
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Chapter Introduction
Chapter 1: Scope of CD30 (TNFRSF8) Antibody, Research Methodology, etc.
Chapter 2: Executive Summary, global CD30 (TNFRSF8) Antibody market size (sales and revenue) and CAGR, CD30 (TNFRSF8) Antibody market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: CD30 (TNFRSF8) Antibody sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global CD30 (TNFRSF8) Antibody sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global CD30 (TNFRSF8) Antibody market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sino Biological, Inc., Bio-Techne, Thermo Fisher Scientific (China) Co., Ltd., Boster Biological Technology, MyBiosource, Inc., Abeomics Inc., Abbexa, Cell Signaling Technology, Inc. and Creative Diagnostics, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for CD30 (TNFRSF8) Antibody by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for CD30 (TNFRSF8) Antibody by Country/Region, 2017, 2022 & 2028
2.2 CD30 (TNFRSF8) Antibody Segment by Type
2.2.1 Monoclonal Antibody
2.2.2 Polyclonal Antibody
2.3 CD30 (TNFRSF8) Antibody Sales by Type
2.3.1 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
2.3.2 Global CD30 (TNFRSF8) Antibody Revenue and Market Share by Type (2017-2022)
2.3.3 Global CD30 (TNFRSF8) Antibody Sale Price by Type (2017-2022)
2.4 CD30 (TNFRSF8) Antibody Segment by Application
2.4.1 Flow Cytometry
2.4.2 ELISA
2.4.3 Western Blot
2.4.4 Immunofluorescence
2.4.5 Other
2.5 CD30 (TNFRSF8) Antibody Sales by Application
2.5.1 Global CD30 (TNFRSF8) Antibody Sale Market Share by Application (2017-2022)
2.5.2 Global CD30 (TNFRSF8) Antibody Revenue and Market Share by Application (2017-2022)
2.5.3 Global CD30 (TNFRSF8) Antibody Sale Price by Application (2017-2022)
3 Global CD30 (TNFRSF8) Antibody by Company
3.1 Global CD30 (TNFRSF8) Antibody Breakdown Data by Company
3.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Company (2020-2022)
3.1.2 Global CD30 (TNFRSF8) Antibody Sales Market Share by Company (2020-2022)
3.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Company (2020-2022)
3.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Company (2020-2022)
3.2.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company (2020-2022)
3.3 Global CD30 (TNFRSF8) Antibody Sale Price by Company
3.4 Key Manufacturers CD30 (TNFRSF8) Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD30 (TNFRSF8) Antibody Product Location Distribution
3.4.2 Players CD30 (TNFRSF8) Antibody Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for CD30 (TNFRSF8) Antibody by Geographic Region
4.1 World Historic CD30 (TNFRSF8) Antibody Market Size by Geographic Region (2017-2022)
4.1.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Geographic Region (2017-2022)
4.1.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Geographic Region
4.2 World Historic CD30 (TNFRSF8) Antibody Market Size by Country/Region (2017-2022)
4.2.1 Global CD30 (TNFRSF8) Antibody Annual Sales by Country/Region (2017-2022)
4.2.2 Global CD30 (TNFRSF8) Antibody Annual Revenue by Country/Region
4.3 Americas CD30 (TNFRSF8) Antibody Sales Growth
4.4 APAC CD30 (TNFRSF8) Antibody Sales Growth
4.5 Europe CD30 (TNFRSF8) Antibody Sales Growth
4.6 Middle East & Africa CD30 (TNFRSF8) Antibody Sales Growth
5 Americas
5.1 Americas CD30 (TNFRSF8) Antibody Sales by Country
5.1.1 Americas CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)
5.1.2 Americas CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)
5.2 Americas CD30 (TNFRSF8) Antibody Sales by Type
5.3 Americas CD30 (TNFRSF8) Antibody Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC CD30 (TNFRSF8) Antibody Sales by Region
6.1.1 APAC CD30 (TNFRSF8) Antibody Sales by Region (2017-2022)
6.1.2 APAC CD30 (TNFRSF8) Antibody Revenue by Region (2017-2022)
6.2 APAC CD30 (TNFRSF8) Antibody Sales by Type
6.3 APAC CD30 (TNFRSF8) Antibody Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe CD30 (TNFRSF8) Antibody by Country
7.1.1 Europe CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)
7.1.2 Europe CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)
7.2 Europe CD30 (TNFRSF8) Antibody Sales by Type
7.3 Europe CD30 (TNFRSF8) Antibody Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa CD30 (TNFRSF8) Antibody by Country
8.1.1 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Country (2017-2022)
8.1.2 Middle East & Africa CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022)
8.2 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Type
8.3 Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody
10.3 Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody
10.4 Industry Chain Structure of CD30 (TNFRSF8) Antibody
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 CD30 (TNFRSF8) Antibody Distributors
11.3 CD30 (TNFRSF8) Antibody Customer
12 World Forecast Review for CD30 (TNFRSF8) Antibody by Geographic Region
12.1 Global CD30 (TNFRSF8) Antibody Market Size Forecast by Region
12.1.1 Global CD30 (TNFRSF8) Antibody Forecast by Region (2023-2028)
12.1.2 Global CD30 (TNFRSF8) Antibody Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global CD30 (TNFRSF8) Antibody Forecast by Type
12.7 Global CD30 (TNFRSF8) Antibody Forecast by Application
13 Key Players Analysis
13.1 Sino Biological, Inc.
13.1.1 Sino Biological, Inc. Company Information
13.1.2 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Offered
13.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Sino Biological, Inc. Main Business Overview
13.1.5 Sino Biological, Inc. Latest Developments
13.2 Bio-Techne
13.2.1 Bio-Techne Company Information
13.2.2 Bio-Techne CD30 (TNFRSF8) Antibody Product Offered
13.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Bio-Techne Main Business Overview
13.2.5 Bio-Techne Latest Developments
13.3 Thermo Fisher Scientific (China) Co., Ltd.
13.3.1 Thermo Fisher Scientific (China) Co., Ltd. Company Information
13.3.2 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Offered
13.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Thermo Fisher Scientific (China) Co., Ltd. Main Business Overview
13.3.5 Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
13.4 Boster Biological Technology
13.4.1 Boster Biological Technology Company Information
13.4.2 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Offered
13.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Boster Biological Technology Main Business Overview
13.4.5 Boster Biological Technology Latest Developments
13.5 MyBiosource, Inc.
13.5.1 MyBiosource, Inc. Company Information
13.5.2 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Offered
13.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 MyBiosource, Inc. Main Business Overview
13.5.5 MyBiosource, Inc. Latest Developments
13.6 Abeomics Inc.
13.6.1 Abeomics Inc. Company Information
13.6.2 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Offered
13.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Abeomics Inc. Main Business Overview
13.6.5 Abeomics Inc. Latest Developments
13.7 Abbexa
13.7.1 Abbexa Company Information
13.7.2 Abbexa CD30 (TNFRSF8) Antibody Product Offered
13.7.3 Abbexa CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Abbexa Main Business Overview
13.7.5 Abbexa Latest Developments
13.8 Cell Signaling Technology, Inc.
13.8.1 Cell Signaling Technology, Inc. Company Information
13.8.2 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Offered
13.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Cell Signaling Technology, Inc. Main Business Overview
13.8.5 Cell Signaling Technology, Inc. Latest Developments
13.9 Creative Diagnostics
13.9.1 Creative Diagnostics Company Information
13.9.2 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Offered
13.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Creative Diagnostics Main Business Overview
13.9.5 Creative Diagnostics Latest Developments
13.10 OriGene Technologies, Inc.
13.10.1 OriGene Technologies, Inc. Company Information
13.10.2 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Offered
13.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 OriGene Technologies, Inc. Main Business Overview
13.10.5 OriGene Technologies, Inc. Latest Developments
13.11 Merck
13.11.1 Merck Company Information
13.11.2 Merck CD30 (TNFRSF8) Antibody Product Offered
13.11.3 Merck CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Merck Main Business Overview
13.11.5 Merck Latest Developments
13.12 Cayman Chemical
13.12.1 Cayman Chemical Company Information
13.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Product Offered
13.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Cayman Chemical Main Business Overview
13.12.5 Cayman Chemical Latest Developments
13.13 CUSABIO
13.13.1 CUSABIO Company Information
13.13.2 CUSABIO CD30 (TNFRSF8) Antibody Product Offered
13.13.3 CUSABIO CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 CUSABIO Main Business Overview
13.13.5 CUSABIO Latest Developments
13.14 Biotium
13.14.1 Biotium Company Information
13.14.2 Biotium CD30 (TNFRSF8) Antibody Product Offered
13.14.3 Biotium CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Biotium Main Business Overview
13.14.5 Biotium Latest Developments
13.15 BioLegend
13.15.1 BioLegend Company Information
13.15.2 BioLegend CD30 (TNFRSF8) Antibody Product Offered
13.15.3 BioLegend CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 BioLegend Main Business Overview
13.15.5 BioLegend Latest Developments
13.16 Abcepta
13.16.1 Abcepta Company Information
13.16.2 Abcepta CD30 (TNFRSF8) Antibody Product Offered
13.16.3 Abcepta CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Abcepta Main Business Overview
13.16.5 Abcepta Latest Developments
13.17 ProSci Incorporated
13.17.1 ProSci Incorporated Company Information
13.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Offered
13.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 ProSci Incorporated Main Business Overview
13.17.5 ProSci Incorporated Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. CD30 (TNFRSF8) Antibody Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. CD30 (TNFRSF8) Antibody Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Monoclonal Antibody
Table 4. Major Players of Polyclonal Antibody
Table 5. Global CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)
Table 6. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
Table 7. Global CD30 (TNFRSF8) Antibody Revenue by Type (2017-2022) & ($ million)
Table 8. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2017-2022)
Table 9. Global CD30 (TNFRSF8) Antibody Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)
Table 11. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Table 12. Global CD30 (TNFRSF8) Antibody Revenue by Application (2017-2022)
Table 13. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2017-2022)
Table 14. Global CD30 (TNFRSF8) Antibody Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global CD30 (TNFRSF8) Antibody Sales by Company (2020-2022) & (K Units)
Table 16. Global CD30 (TNFRSF8) Antibody Sales Market Share by Company (2020-2022)
Table 17. Global CD30 (TNFRSF8) Antibody Revenue by Company (2020-2022) ($ Millions)
Table 18. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company (2020-2022)
Table 19. Global CD30 (TNFRSF8) Antibody Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers CD30 (TNFRSF8) Antibody Producing Area Distribution and Sales Area
Table 21. Players CD30 (TNFRSF8) Antibody Products Offered
Table 22. CD30 (TNFRSF8) Antibody Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global CD30 (TNFRSF8) Antibody Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global CD30 (TNFRSF8) Antibody Sales Market Share Geographic Region (2017-2022)
Table 27. Global CD30 (TNFRSF8) Antibody Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global CD30 (TNFRSF8) Antibody Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global CD30 (TNFRSF8) Antibody Sales Market Share by Country/Region (2017-2022)
Table 31. Global CD30 (TNFRSF8) Antibody Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)
Table 34. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)
Table 35. Americas CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)
Table 37. Americas CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)
Table 38. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
Table 39. Americas CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)
Table 40. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Table 41. APAC CD30 (TNFRSF8) Antibody Sales by Region (2017-2022) & (K Units)
Table 42. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Region (2017-2022)
Table 43. APAC CD30 (TNFRSF8) Antibody Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC CD30 (TNFRSF8) Antibody Revenue Market Share by Region (2017-2022)
Table 45. APAC CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)
Table 46. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
Table 47. APAC CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)
Table 48. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Table 49. Europe CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)
Table 50. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)
Table 51. Europe CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)
Table 53. Europe CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)
Table 54. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
Table 55. Europe CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)
Table 56. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa CD30 (TNFRSF8) Antibody Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of CD30 (TNFRSF8) Antibody
Table 66. Key Market Challenges & Risks of CD30 (TNFRSF8) Antibody
Table 67. Key Industry Trends of CD30 (TNFRSF8) Antibody
Table 68. CD30 (TNFRSF8) Antibody Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. CD30 (TNFRSF8) Antibody Distributors List
Table 71. CD30 (TNFRSF8) Antibody Customer List
Table 72. Global CD30 (TNFRSF8) Antibody Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global CD30 (TNFRSF8) Antibody Sales Market Forecast by Region
Table 74. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC CD30 (TNFRSF8) Antibody Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC CD30 (TNFRSF8) Antibody Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global CD30 (TNFRSF8) Antibody Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Type (2023-2028)
Table 86. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global CD30 (TNFRSF8) Antibody Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global CD30 (TNFRSF8) Antibody Sales Market Share Forecast by Application (2023-2028)
Table 90. Global CD30 (TNFRSF8) Antibody Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global CD30 (TNFRSF8) Antibody Revenue Market Share Forecast by Application (2023-2028)
Table 92. Sino Biological, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 93. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Offered
Table 94. Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Sino Biological, Inc. Main Business
Table 96. Sino Biological, Inc. Latest Developments
Table 97. Bio-Techne Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 98. Bio-Techne CD30 (TNFRSF8) Antibody Product Offered
Table 99. Bio-Techne CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Bio-Techne Main Business
Table 101. Bio-Techne Latest Developments
Table 102. Thermo Fisher Scientific (China) Co., Ltd. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 103. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Offered
Table 104. Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Thermo Fisher Scientific (China) Co., Ltd. Main Business
Table 106. Thermo Fisher Scientific (China) Co., Ltd. Latest Developments
Table 107. Boster Biological Technology Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 108. Boster Biological Technology CD30 (TNFRSF8) Antibody Product Offered
Table 109. Boster Biological Technology CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Boster Biological Technology Main Business
Table 111. Boster Biological Technology Latest Developments
Table 112. MyBiosource, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 113. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Offered
Table 114. MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. MyBiosource, Inc. Main Business
Table 116. MyBiosource, Inc. Latest Developments
Table 117. Abeomics Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 118. Abeomics Inc. CD30 (TNFRSF8) Antibody Product Offered
Table 119. Abeomics Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Abeomics Inc. Main Business
Table 121. Abeomics Inc. Latest Developments
Table 122. Abbexa Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 123. Abbexa CD30 (TNFRSF8) Antibody Product Offered
Table 124. Abbexa CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Abbexa Main Business
Table 126. Abbexa Latest Developments
Table 127. Cell Signaling Technology, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 128. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Offered
Table 129. Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Cell Signaling Technology, Inc. Main Business
Table 131. Cell Signaling Technology, Inc. Latest Developments
Table 132. Creative Diagnostics Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 133. Creative Diagnostics CD30 (TNFRSF8) Antibody Product Offered
Table 134. Creative Diagnostics CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Creative Diagnostics Main Business
Table 136. Creative Diagnostics Latest Developments
Table 137. OriGene Technologies, Inc. Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 138. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Offered
Table 139. OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. OriGene Technologies, Inc. Main Business
Table 141. OriGene Technologies, Inc. Latest Developments
Table 142. Merck Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 143. Merck CD30 (TNFRSF8) Antibody Product Offered
Table 144. Merck CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Merck Main Business
Table 146. Merck Latest Developments
Table 147. Cayman Chemical Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 148. Cayman Chemical CD30 (TNFRSF8) Antibody Product Offered
Table 149. Cayman Chemical CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. Cayman Chemical Main Business
Table 151. Cayman Chemical Latest Developments
Table 152. CUSABIO Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 153. CUSABIO CD30 (TNFRSF8) Antibody Product Offered
Table 154. CUSABIO CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. CUSABIO Main Business
Table 156. CUSABIO Latest Developments
Table 157. Biotium Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 158. Biotium CD30 (TNFRSF8) Antibody Product Offered
Table 159. Biotium CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. Biotium Main Business
Table 161. Biotium Latest Developments
Table 162. BioLegend Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 163. BioLegend CD30 (TNFRSF8) Antibody Product Offered
Table 164. BioLegend CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 165. BioLegend Main Business
Table 166. BioLegend Latest Developments
Table 167. Abcepta Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 168. Abcepta CD30 (TNFRSF8) Antibody Product Offered
Table 169. Abcepta CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 170. Abcepta Main Business
Table 171. Abcepta Latest Developments
Table 172. ProSci Incorporated Basic Information, CD30 (TNFRSF8) Antibody Manufacturing Base, Sales Area and Its Competitors
Table 173. ProSci Incorporated CD30 (TNFRSF8) Antibody Product Offered
Table 174. ProSci Incorporated CD30 (TNFRSF8) Antibody Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 175. ProSci Incorporated Main Business
Table 176. ProSci Incorporated Latest Developments
List of Figures
Figure 1. Picture of CD30 (TNFRSF8) Antibody
Figure 2. CD30 (TNFRSF8) Antibody Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CD30 (TNFRSF8) Antibody Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global CD30 (TNFRSF8) Antibody Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. CD30 (TNFRSF8) Antibody Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Monoclonal Antibody
Figure 10. Product Picture of Polyclonal Antibody
Figure 11. Global CD30 (TNFRSF8) Antibody Sales Market Share by Type in 2021
Figure 12. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2017-2022)
Figure 13. CD30 (TNFRSF8) Antibody Consumed in Flow Cytometry
Figure 14. Global CD30 (TNFRSF8) Antibody Market: Flow Cytometry (2017-2022) & (K Units)
Figure 15. CD30 (TNFRSF8) Antibody Consumed in ELISA
Figure 16. Global CD30 (TNFRSF8) Antibody Market: ELISA (2017-2022) & (K Units)
Figure 17. CD30 (TNFRSF8) Antibody Consumed in Western Blot
Figure 18. Global CD30 (TNFRSF8) Antibody Market: Western Blot (2017-2022) & (K Units)
Figure 19. CD30 (TNFRSF8) Antibody Consumed in Immunofluorescence
Figure 20. Global CD30 (TNFRSF8) Antibody Market: Immunofluorescence (2017-2022) & (K Units)
Figure 21. CD30 (TNFRSF8) Antibody Consumed in Other
Figure 22. Global CD30 (TNFRSF8) Antibody Market: Other (2017-2022) & (K Units)
Figure 23. Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2017-2022)
Figure 24. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application in 2021
Figure 25. CD30 (TNFRSF8) Antibody Revenue Market by Company in 2021 ($ Million)
Figure 26. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Company in 2021
Figure 27. Global CD30 (TNFRSF8) Antibody Sales Market Share by Geographic Region (2017-2022)
Figure 28. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Geographic Region in 2021
Figure 29. Global CD30 (TNFRSF8) Antibody Sales Market Share by Region (2017-2022)
Figure 30. Global CD30 (TNFRSF8) Antibody Revenue Market Share by Country/Region in 2021
Figure 31. Americas CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)
Figure 32. Americas CD30 (TNFRSF8) Antibody Revenue 2017-2022 ($ Millions)
Figure 33. APAC CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)
Figure 34. APAC CD30 (TNFRSF8) Antibody Revenue 2017-2022 ($ Millions)
Figure 35. Europe CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)
Figure 36. Europe CD30 (TNFRSF8) Antibody Revenue 2017-2022 ($ Millions)
Figure 37. Middle East & Africa CD30 (TNFRSF8) Antibody Sales 2017-2022 (K Units)
Figure 38. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue 2017-2022 ($ Millions)
Figure 39. Americas CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021
Figure 40. Americas CD30 (TNFRSF8) Antibody Revenue Market Share by Country in 2021
Figure 41. United States CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 42. Canada CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 43. Mexico CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 44. Brazil CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 45. APAC CD30 (TNFRSF8) Antibody Sales Market Share by Region in 2021
Figure 46. APAC CD30 (TNFRSF8) Antibody Revenue Market Share by Regions in 2021
Figure 47. China CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 48. Japan CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 49. South Korea CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 50. Southeast Asia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 51. India CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 52. Australia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 53. Europe CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021
Figure 54. Europe CD30 (TNFRSF8) Antibody Revenue Market Share by Country in 2021
Figure 55. Germany CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 56. France CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 57. UK CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 58. Italy CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 59. Russia CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 60. Middle East & Africa CD30 (TNFRSF8) Antibody Sales Market Share by Country in 2021
Figure 61. Middle East & Africa CD30 (TNFRSF8) Antibody Revenue Market Share by Country in 2021
Figure 62. Egypt CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 63. South Africa CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 64. Israel CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 65. Turkey CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 66. GCC Country CD30 (TNFRSF8) Antibody Revenue Growth 2017-2022 ($ Millions)
Figure 67. Manufacturing Cost Structure Analysis of CD30 (TNFRSF8) Antibody in 2021
Figure 68. Manufacturing Process Analysis of CD30 (TNFRSF8) Antibody
Figure 69. Industry Chain Structure of CD30 (TNFRSF8) Antibody
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets